Recommendations for Clinical Trial Development in Follicular Lymphoma

Kami Maddocks; Paul M Barr; Bruce D Cheson; Richard F Little; Lawrence Baizer; Brad S Kahl; John P Leonard; Nathan Fowler; Leo I Gordon; Brian K Link; Jonathan W Friedberg; Stephen M Ansell

doi:10.1093/jnci/djw255

Back

Recommendations for Clinical Trial Development in Follicular Lymphoma

Journal article

Open access

Peer reviewed

Recommendations for Clinical Trial Development in Follicular Lymphoma

Kami Maddocks, Paul M Barr, Bruce D Cheson, Richard F Little, Lawrence Baizer, Brad S Kahl, John P Leonard, Nathan Fowler, Leo I Gordon, Brian K Link, …

JNCI : Journal of the National Cancer Institute, Vol.109(3), p.djw255

03/2017

DOI: 10.1093/jnci/djw255

PMCID: PMC6059137

PMID: 28040699

Files and links (1)

url

https://doi.org/10.1093/jnci/djw255View

Published (Version of record) Open Access

Abstract

Follicular lymphoma (FL) is the second most common lymphoid malignancy, representing 20% to 25% of all cases of non-Hodgkin's lymphoma (NHL), and the most common of the indolent NHLs. FL is considered incurable in the majority of patients with the current standard therapeutic approaches, although outcomes have improved in the last few decades with our current therapies, with a median overall survival that now exceeds 18 years. While the majority of patients with FL have improved outcomes with our current therapeutic approaches, there are patients with high-risk disease features that have inferior outcomes to these therapies. There is an urgent need to integrate novel therapeutic agents into the treatment regimens for these patients to improve outcomes with continued evaluation of biomarkers indicative of prognosis and effects of these regimens on quality of life.

Quality of Life

Antineoplastic Combined Chemotherapy Protocols - therapeutic use

Biomarkers, Tumor - metabolism

Clinical Trials as Topic

Disease Progression

Endpoint Determination

Humans

Lymphoma, Follicular - therapy

Lymphoma, Non-Hodgkin - therapy

Patient Selection

Prognosis

Research Design

Treatment Outcome

Details

Title: Subtitle: Recommendations for Clinical Trial Development in Follicular Lymphoma
Creators: Kami Maddocks - The Ohio State University
Paul M Barr - University of Rochester
Bruce D Cheson - Georgetown University
Richard F Little - National Institutes of Health
Lawrence Baizer - National Institutes of Health
Brad S Kahl - Washington University in St. Louis
John P Leonard - Cornell University
Nathan Fowler - The University of Texas Health Science Center at Houston
Leo I Gordon - Northwestern University
Brian K Link - University of Iowa
Jonathan W Friedberg - University of Rochester
Stephen M Ansell - Mayo Clinic
Resource Type: Journal article
Publication Details: JNCI : Journal of the National Cancer Institute, Vol.109(3), p.djw255
DOI: 10.1093/jnci/djw255
PMID: 28040699
PMCID: PMC6059137
ISSN: 0027-8874
eISSN: 1460-2105
Grant note: U10 CA180888 / NCI NIH HHS P30 CA086862 / NCI NIH HHS
Language: English
Date published: 03/2017
Academic Unit: Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
Record Identifier: 9984359579602771

Metrics

10 Record Views

19 Times Cited - Web of Science

See more details